Relmada Therapeutics Inc (RLMD)
Relmada Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies in the United States. Its lead program, NDV-01, is a controlled-release intravesical combination of gemcitabine and docetaxel that is being evaluated in Phase 2 studies for aggressive forms of non-muscle invasive bladder cancer. The company is also advancing Sepranolone, a neurosteroid epimer of allopregnanolone that is Phase 2b-ready and being studied for potential use in prader-willi syndrome, tourette syndrome, excessive tremor, and other conditions associated with excessive GABAergic activity. Relmada has an agreement with Asarina Pharma AB and Trigone. Founded in 2004, the company is headquartered in Coral Gables, Florida.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-RLMD
|
$4.57
|
7.9% Upside
|
Fair
|
$10.75
|
153.5% Upside
|
Bargain
|
Fair
|
0.0%
|
November 5, 2026
|
2.1x
|
452.3 M
|
226 M
|
0.0%
|
72.9%
|
17.2
|
74.3%
|
